Emergent BioSolutions Inc. (0IGA.L)
USD 4.66
(2.44%)
USD 4.66
(2.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.04 Billion USD | -21.7% |
| 2022 | 593.2 Million USD | -7.44% |
| 2021 | 640.9 Million USD | 7.25% |
| 2020 | 597.6 Million USD | 7.02% |
| 2019 | 558.4 Million USD | 50.8% |
| 2018 | 370.3 Million USD | 53.73% |
| 2017 | 240.88 Million USD | -4.4% |
| 2016 | 251.97 Million USD | -16.69% |
| 2015 | 302.45 Million USD | 10.52% |
| 2014 | 273.67 Million USD | 31.69% |
| 2013 | 207.81 Million USD | 5.9% |
| 2012 | 196.24 Million USD | -1.44% |
| 2011 | 199.11 Million USD | 20.31% |
| 2010 | 165.5 Million USD | 11.54% |
| 2009 | 148.37 Million USD | 29.53% |
| 2008 | 114.54 Million USD | 4.6% |
| 2007 | 109.51 Million USD | 21.54% |
| 2006 | 90.1 Million USD | 76.07% |
| 2005 | 51.17 Million USD | 26.54% |
| 2004 | 40.44 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 16.2 Million USD | -98.14% |
| 2001 | 869.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 104.6 Million USD | 5.02% |
| 2024 Q1 | 99.6 Million USD | -14.65% |
| 2023 Q3 | 117.6 Million USD | -11.91% |
| 2023 Q4 | 116.7 Million USD | -0.77% |
| 2023 Q2 | 133.5 Million USD | -15.56% |
| 2023 Q1 | 158.1 Million USD | -6.84% |
| 2023 FY | 464.5 Million USD | -21.7% |
| 2022 Q2 | 144.9 Million USD | -0.21% |
| 2022 Q1 | 145.2 Million USD | -24.06% |
| 2022 FY | 593.2 Million USD | -7.44% |
| 2022 Q3 | 133.4 Million USD | -7.94% |
| 2022 Q4 | 169.7 Million USD | 27.21% |
| 2021 FY | 640.9 Million USD | 7.25% |
| 2021 Q1 | 148.3 Million USD | -5.3% |
| 2021 Q2 | 155.2 Million USD | 4.65% |
| 2021 Q3 | 146.2 Million USD | -5.8% |
| 2021 Q4 | 191.2 Million USD | 30.78% |
| 2020 Q2 | 138.9 Million USD | 9.2% |
| 2020 Q3 | 174.9 Million USD | 25.92% |
| 2020 Q1 | 127.2 Million USD | -15.09% |
| 2020 Q4 | 156.6 Million USD | -10.46% |
| 2020 FY | 597.6 Million USD | 7.02% |
| 2019 Q1 | 126 Million USD | -13.88% |
| 2019 FY | 558.4 Million USD | 50.8% |
| 2019 Q2 | 149.4 Million USD | 18.57% |
| 2019 Q3 | 133.1 Million USD | -10.91% |
| 2019 Q4 | 149.8 Million USD | 12.55% |
| 2018 Q3 | 79.11 Million USD | 23.13% |
| 2018 Q2 | 64.25 Million USD | -7.23% |
| 2018 FY | 370.3 Million USD | 53.73% |
| 2018 Q1 | 69.25 Million USD | -1.73% |
| 2018 Q4 | 146.3 Million USD | 84.93% |
| 2017 Q2 | 57.61 Million USD | 3.58% |
| 2017 FY | 240.88 Million USD | -4.4% |
| 2017 Q1 | 55.62 Million USD | -10.96% |
| 2017 Q4 | 70.47 Million USD | 23.29% |
| 2017 Q3 | 57.16 Million USD | -0.79% |
| 2016 Q3 | 67.87 Million USD | -14.62% |
| 2016 Q1 | 73.93 Million USD | -5.74% |
| 2016 FY | 251.97 Million USD | -16.69% |
| 2016 Q4 | 62.47 Million USD | -7.96% |
| 2016 Q2 | 79.49 Million USD | 7.52% |
| 2015 FY | 302.45 Million USD | 10.52% |
| 2015 Q4 | 78.44 Million USD | 6.83% |
| 2015 Q3 | 73.42 Million USD | -5.13% |
| 2015 Q2 | 77.39 Million USD | 5.74% |
| 2015 Q1 | 73.19 Million USD | 3.28% |
| 2014 Q3 | 74.49 Million USD | 9.63% |
| 2014 Q4 | 70.87 Million USD | -4.87% |
| 2014 FY | 273.67 Million USD | 31.69% |
| 2014 Q1 | 60.34 Million USD | 8.94% |
| 2014 Q2 | 67.95 Million USD | 12.61% |
| 2013 Q3 | 50.89 Million USD | 0.22% |
| 2013 FY | 207.81 Million USD | 5.9% |
| 2013 Q1 | 50.75 Million USD | -8.42% |
| 2013 Q4 | 55.39 Million USD | 8.84% |
| 2013 Q2 | 50.77 Million USD | 0.05% |
| 2012 FY | 196.24 Million USD | -1.44% |
| 2012 Q4 | 55.42 Million USD | 19.07% |
| 2012 Q3 | 46.54 Million USD | -4.11% |
| 2012 Q2 | 48.54 Million USD | 6.13% |
| 2012 Q1 | 45.73 Million USD | -3.97% |
| 2011 Q4 | 47.63 Million USD | 2.11% |
| 2011 Q1 | 52.97 Million USD | 3.29% |
| 2011 Q2 | 51.86 Million USD | -2.09% |
| 2011 Q3 | 46.64 Million USD | -10.06% |
| 2011 FY | 199.11 Million USD | 20.31% |
| 2010 Q2 | 36.25 Million USD | 0.38% |
| 2010 Q1 | 36.11 Million USD | -4.7% |
| 2010 Q3 | 41.84 Million USD | 15.44% |
| 2010 Q4 | 51.28 Million USD | 22.55% |
| 2010 FY | 165.5 Million USD | 11.54% |
| 2009 Q2 | 40.05 Million USD | 25.62% |
| 2009 FY | 148.37 Million USD | 29.53% |
| 2009 Q4 | 37.89 Million USD | -1.67% |
| 2009 Q3 | 38.53 Million USD | -3.78% |
| 2009 Q1 | 31.88 Million USD | 13.77% |
| 2008 Q1 | 23.53 Million USD | -18.66% |
| 2008 FY | 114.54 Million USD | 4.6% |
| 2008 Q4 | 28.02 Million USD | -8.83% |
| 2008 Q3 | 30.74 Million USD | -4.66% |
| 2008 Q2 | 32.24 Million USD | 37.01% |
| 2007 Q3 | 27.81 Million USD | 6.98% |
| 2007 Q4 | 28.93 Million USD | 4.03% |
| 2007 Q1 | 26.76 Million USD | -12.28% |
| 2007 FY | 109.51 Million USD | 21.54% |
| 2007 Q2 | 26 Million USD | -2.85% |
| 2006 Q3 | 19.86 Million USD | 0.0% |
| 2006 Q4 | 30.51 Million USD | 53.59% |
| 2006 FY | 90.1 Million USD | 76.07% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 100.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 100.0% |
| 2005 FY | 51.17 Million USD | 26.54% |
| 2005 Q4 | -82.77 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | 40.44 Million USD | 0.0% |
| 2004 Q4 | -70.54 Million USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2002 FY | 16.2 Million USD | -98.14% |
| 2001 Q1 | 301.1 Million USD | 31.77% |
| 2001 Q2 | 495.9 Million USD | 64.7% |
| 2001 Q3 | 363.7 Million USD | -26.66% |
| 2001 FY | 869.5 Million USD | 0.0% |
| 2001 Q4 | 228.5 Million USD | -37.17% |
| 2000 Q4 | 228.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 89.819% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -155.378% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -278.682% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -632.822% |
| uniQure N.V. | 285.08 Million USD | -266.205% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -144.124% |
| bluebird bio, Inc. | 240.23 Million USD | -334.58% |
| Imunon, Inc. | 21.03 Million USD | -4864.235% |
| Dynavax Technologies Corporation | 219.14 Million USD | -376.397% |
| Editas Medicine, Inc. | 247.3 Million USD | -322.152% |
| Illumina, Inc. | 3.81 Billion USD | 72.62% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -131.489% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 49.148% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 4.167% |
| Myriad Genetics, Inc. | 600.1 Million USD | -73.971% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 34.607% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 23.281% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -97.349% |
| Verastem, Inc. | 92.08 Million USD | -1033.747% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 97.429% |
| Waters Corporation | 943.51 Million USD | -10.65% |
| Biogen Inc. | 5.2 Billion USD | 79.942% |
| Nektar Therapeutics | 190.9 Million USD | -446.875% |
| Perrigo Company plc | 1.52 Billion USD | 31.698% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -7405.586% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -765.263% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2237.296% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 40.216% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -356.533% |
| Evolus, Inc. | 189.75 Million USD | -450.172% |
| Adicet Bio, Inc. | 152.03 Million USD | -586.67% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -8498.962% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 62.917% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -283.969% |
| FibroGen, Inc. | 398.11 Million USD | -162.237% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 50.638% |
| OPKO Health, Inc. | 574.68 Million USD | -81.664% |
| Homology Medicines, Inc. | 9.87 Million USD | -10472.152% |
| Geron Corporation | 70.44 Million USD | -1382.091% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 42.002% |
| Exelixis, Inc. | 1.58 Billion USD | 34.206% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -935.437% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1772.444% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -89.279% |
| Zoetis Inc. | 2.76 Billion USD | 62.242% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -119.162% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -2052.489% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 78.136% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -2566.462% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -33.917% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -183.225% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -248.793% |
| Blueprint Medicines Corporation | 722.86 Million USD | -44.426% |
| Insmed Incorporated | 949.26 Million USD | -9.98% |
| TG Therapeutics, Inc. | 198.47 Million USD | -426.011% |
| Incyte Corporation | 1.19 Billion USD | 12.305% |